The Life Science Cluster is growing and has welcomed five more members. “Slowly putting corona behind us, we are very pleased to expand our membership base with more international pharmaceutical companies, as well as a new investor and a provider of digital platforms”. Says Hanne Mette Dyrlie Kristensen, CEO of The Life Science Cluster.

By the summer 2021, The Life Science Cluster has over 90 members. Among the new members we find three pharmaceutical companies: Roche Norge AS, AstraZeneca Norway AS and Bristol Myers Squibb AS, in addition to Admincontrol and Farvatn Venture AS.

“All our new members will contribute to unleashing the potential of life science in Norway and bring needed solutions to society”, says Hanne Mette Dyrlie Kristensen.

Roche Norway AS

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. As the world’s largest biotech company, Roche is developing truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

“The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare” says Kristin Krogsrud, External Affairs Partner Roche Norge.

Roche is working with partners across the healthcare sector to provide the best care for each person. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide.

“In Norway, Roche’s aim is to act as a true partner in the national health care system. We focus on impactful public-private partnerships and collaboration with multiple stakeholders and partners. Our overarching aim is to provide better outcomes for more patients faster.”

“The membership of The Life Science Cluster will provide us a platform for networking and partnering with other companies and stakeholders that are active in life sciences in Norway. We also expect that The Life Science Cluster will focus on creating an environment for scientific and medical innovation and hope that we can play an active part in this”, says Kristin Krogsrud.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical business with innovative medicines used by millions of patients worldwide. AstraZeneca is focused on enhanced innovation and the delivery of life-changing medicines that contribute value to patients and society.

The business is organised to deliver the strategic priorities; sustainably, supporting continued scientific innovation and commercial success. The focus is on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

“Our goal is to accelerate innovative science, advance high-potential late-stage pipeline projects and pursue the next wave of disruptive biology and accelerating efforts in AI, data science. All to enhance and prolong the lives of patients. We look forward to being part of The Life Science Cluster and a network that can help us reach this goal, says Benedikte Akre and Kristin Løseth at AstraZeneca.

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

“We combine the agility of biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company,” says Britt Hestenes, Governmental Affairs Manager at Bristol Myers Squibb.

“We believe in the power of science to address some of the most challenging diseases of our time. In oncology, hematology, immunology and cardiovascular disease – and one of the most diverse and promising pipelines in the industry – we focus on innovations that drive meaningful change,” says Britt Hestenes.

Bristol Myers Squibb has over 30.000 employees on a global basis, in Norway there are approximately 40 employees.

The company’s R&D organization is composed of industry-leading researchers and drug developers who have a passion for science, a curiosity for discovery and a commitment to translating these advances into medicines that make a difference for patients. Supported by robust capabilities, unmatched collective experience and a strong, global presence, the company is advancing science through internally discovered medicines as well as external partnerships.

“Partnership and collaboration are essential to our strategy. We anchor ourselves within vibrant healthcare innovation ecosystems, such as The Life Science Cluster, where academic research centers and biotech and biopharma companies all contribute to continued scientific advancement,” says Britt Hestenes.

Varevatn AS

Farvatn is a Norwegian family-owned investment company seeking to preserve and grow their wealth while leaving a positive footprint on the world.

The company is continuously looking for new investment opportunities with attractive long-term, risk-adjusted returns and seek to direct capital towards exceptional ideas, teams and capital partners.

Share This